Creative Medical Technology Hol (CELZ) Fair Value 2026

CELZ · Biological Products, (No Diagnostic Substances) ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.0 /10

32 fundamental signals · 11 models active

Value Trap Risk

LOW (32/100)

Quick Summary — As of 2026-07-15, Creative Medical Technology Hol (CELZ) trades at $0.82, approximately 25% below CirclFi’s Bayesian DCF fair value of $1.10. QOC: 6.0/10. Value Trap Risk: 32/100 (LOW). 11/13 models active.

Key Facts

Ticker
CELZ
Price
$0.82
Quality Score
6.0/10
Value Trap Risk
32/100
Models Active
11/13
Last Updated
Strength: CUCE Ensemble suggests +100.6% upside with 7% confidence
Risk: Limited model coverage (11/13) may reduce confidence

Is Creative Medical Technology Hol (CELZ) Undervalued or Overvalued in 2026?

According to CirclFi’s 11-model valuation engine, Creative Medical Technology Hol (CELZ) appears undervalued as of : the median of 11 independent fair value estimates is $1.55, 88.3% above the current price of $0.82. Estimates range from $0.10 to $4.26. CELZ scores 6.0/10 on fundamental quality and 32/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Creative Medical Technology Hol Stock in 2026? →

Valuation Matrix

11 Intrinsic Value Models vs. Current Price ($0.82)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $1.10 +33.4%
Earnings Power Value
Low Conviction
 $1.47 +79.2%
CUCE Ensemble
Low Conviction
 $1.65 +100.6%
First Chicago
Medium Conviction
 $1.55 +88.3%

Unlock the Full Matrix

Access 7 additional models including EROIC Spread, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 11 Models →

Cancel anytime · No contracts · Instant access

What Is Creative Medical Technology Hol (CELZ) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Creative Medical Technology Hol is potentially undervalued at its current price of $0.82. Based on our 13-model framework, Creative Medical Technology Hol's intrinsic value is estimated at a composite fair value of $1.74 — representing +112.1% implied upside — with 10 out of 11 active models confirming this thesis. Model dispersion is worth noting: EROIC targets $4.26 (+417.8%), versus ML-RIV at $0.10 (-88.2%). This +506.0% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About CELZ?

11 of 13 models are currently active for CELZ. Of these, 10 models suggest upside while 1 model suggests overvaluation. The Bayesian DCF estimates CELZ's intrinsic value at $1.10, implying +33.4% upside from the current price. See which stocks rank higher →

How Does CELZ Rank in Biological Products, (No Diagnostic Substances)?

Among 134 Biological Products, (No Diagnostic Substances) stocks, CELZ ranks #42 by Quality of Company score. CirclFi's QOC score of 6.0/10 evaluates 32 fundamental signals. A score of 6.0 indicates above-average quality.

See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →

Creative Medical Technology Hol operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is CELZ a Value Trap?

CirclFi's Value Trap algorithm assigns CELZ a score of 32/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

11 of 13 models are active for Creative Medical Technology Hol. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Creative Medical Technology Hol earns a quality score of 6.0/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +506.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CELZ valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CELZ's 11 active models, average confidence is 23%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Creative Medical Technology Hol Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biological Products, (No Diagnostic Substances) Stocks Should You Also Analyze?

8 related Biological Products, (No Diagnostic Substances) stocks with 13-model coverage

EXELExelixis, Inc.QOC 10.0HALOHalozyme Therapeutics, Inc.QOC 10.0NBIXNeurocrine Biosciences, Inc.QOC 10.0GILDGilead Sciences, Inc.QOC 9.7PLXProtalix BioTherapeutics, Inc. QOC 8.6BIIBBiogen Inc.QOC 8.4IMCRImmunocore Holdings plcQOC 7.9TECHBio-Techne CorpQOC 7.8

Read investment analysis: EXEL · HALO · NBIX · GILD · PLX

See all Biological Products, (No Diagnostic Substances) stocks ranked →

Frequently Asked Questions About Creative Medical Technology Hol

What is Creative Medical Technology Hol's intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Creative Medical Technology Hol (CELZ) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $1.10. The Quality of Company score is 6.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CELZ overvalued or undervalued right now?

At $0.82, 10 of 11 active models suggest CELZ may be undervalued, while 1 indicate potential overvaluation. The median of all 11 fair value estimates is $1.55, 88.3% above the current price of $0.82 — a consensus view that CELZ is undervalued. The assessment depends on which methodology best fits Creative Medical Technology Hol's business model in Biological Products, (No Diagnostic Substances).

What does a Quality of Company score of 6.0 mean for CELZ?

Creative Medical Technology Hol's QOC of 6.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on CELZ?

CirclFi analyzes CELZ with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 11 of 13 are active for this stock. Read the full methodology →

Is CELZ a value trap in 2026?

Creative Medical Technology Hol's Value Trap score is 32/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 11-model valuation engine, Creative Medical Technology Hol (CELZ) has a median fair value of $1.55 — 88.3% above the current price of $0.82 — as of 2026-07-15.” Source: circlfi.com/stock/CELZ/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 11 mathematical frameworks give you clarity on CELZ.

Unlock All 11 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access